MCL1 and lymphoma: Here we delve deeper into this result, showing that loss of BAX is also a hit when such screens are performed in Trp53-deficient Eμ-Myc lymphoma cells, and additionally arises as the key mediator of resistance in longer-term CRISPR/Cas9 gene KO screens using suboptimal doses of MCL-1 inhibitors.